1. Home
  2. TNXP vs ALEC Comparison

TNXP vs ALEC Comparison

Compare TNXP & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$11.24

Market Cap

199.7M

Sector

Health Care

ML Signal

HOLD

Logo Alector Inc.

ALEC

Alector Inc.

HOLD

Current Price

$1.58

Market Cap

167.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
ALEC
Founded
2007
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.7M
167.6M
IPO Year
2008
2019

Fundamental Metrics

Financial Performance
Metric
TNXP
ALEC
Price
$11.24
$1.58
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$4.83
AVG Volume (30 Days)
505.8K
474.4K
Earning Date
05-11-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
91.75
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
$21,045,000.00
Revenue This Year
$558.11
$2.03
Revenue Next Year
$38.29
$29.87
P/E Ratio
N/A
N/A
Revenue Growth
29.85
N/A
52 Week Low
$9.40
$1.09
52 Week High
$69.65
$3.40

Technical Indicators

Market Signals
Indicator
TNXP
ALEC
Relative Strength Index (RSI) N/A 43.31
Support Level N/A $1.37
Resistance Level N/A $1.60
Average True Range (ATR) 0.00 0.09
MACD 0.00 0.01
Stochastic Oscillator 0.00 45.00

Price Performance

Historical Comparison
TNXP
ALEC

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About ALEC Alector Inc.

Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.

Share on Social Networks: